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Abstract 23 
 24 
We investigated the serum concentrations of two brominated flame retardants (BFRs) – 25 
polybrominated diphenyl ethers (PBDEs) and hexabromocyclododecane (HBCDD) –in 59 26 
women aged between 23 and 42 from the United Kingdom. We also collected demographic 27 
data, including age, bodyweight and height in order to test for associations with BFR levels. 28 
Temporal and global differences were also assessed using previously published data. 29 
HBCDD was detected in 68% of samples with a mean concentration of 2.2 ng/g lipid (range 30 
= <0.3 – 13 ng/g lipid). The dominant stereoisomer was α-HBCDD with an average 31 
contribution of 82% (0-100%) towards ΣHBCDD, was followed by γ-HBCDD (average 32 
contribution = 17%). PBDEs were detected in 95% of samples with a mean ∑PBDE (sum of 33 
BDEs -28, -47, -99, -100, -153, -154 and -183) concentration of 2.4 ng/g lipid (range = <0.4 – 34 
15 ng/g lipid). BDEs -153 and -47 were the dominant congeners, contributing an average of 35 
40% and 37% respectively, to the average ΣPBDE congener profile.  36 
Data from this study suggests that HBCDD levels decrease with age, it also suggests a 37 
positive association between bodyweight and HBCDD levels, which likewise requires a 38 
large-scale study to confirm this. The data also show that 10 years after their European ban, 39 
PBDE body burden has begun to decrease in the UK. Whilst it is too early to draw any firm 40 
conclusions for HBCDDs, they appear to be following a similar pattern to PBDEs, with levels 41 
decreasing by a factor of >2.5 since 2010. Whilst the human body burden appear to be 42 
decreasing, both PBDEs and HBCDD are still consistently detected in human serum, despite 43 
legislative action limiting their production and use. This highlights the need to continuously 44 
assess human exposure and the effectiveness of policy aimed at reducing exposure.    45 
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1.0 Introduction 46 
Hexabromocyclododecane (HBCDD) and polybrominated diphenyl ethers (PBDEs) have 47 
been used extensively worldwide as brominated flame retardants (BFRs) in a wide variety of 48 
commercial, domestic and industrial applications.  There are three commercial PBDE 49 
formulations – Penta-, Octa- and DecaBDE. The main PBDE applications include electrical 50 
and electronic equipment (EEE - such as TVs, PCs and small domestic appliances) (European 51 
Commission, 2011), soft furnishings (e.g. sofas, mattresses, pillows and curtains) (United 52 
Nations Environment Programme (UNEP), 2010) and in polyurethane foam (PUF) seat 53 
fillings used in automobiles (European Chemicals Bureau, 2000). The primary use of 54 
HBCDD is to flame retard expanded and extruded polystyrene (EPS/XPS) used in building 55 
insulation foam (European Chemicals Agency, 2009). As of 2001 (the last reliable figures 56 
publicly available), Europe accounted for 2 %, 16 %, 14 % and 57 % of the annual global 57 
demand for Penta-, Octa-, DecaBDE and HBCDD respectively (Bromine Science and 58 
Environmental Forum (BSEF), 2003). 59 
 60 
Both PBDEs and HBCDD are lipophilic and resistant to metabolism allowing them to 61 
bioaccumulate in the liver and other fatty tissues. They have long half-lives in humans of 62 
approximately 664 – 2380 days and 64 days for PBDEs and HBCDD, respectively (Geyer et 63 
al., 2004), and have been associated with adverse health effects in humans.. For example, 64 
PBDEs are thought to disrupt levels of sex hormones, including luteinising hormone and 65 
follicle stimulating hormone in men (Meeker et al., 2009), in addition to other toxic effects 66 
including disruption to the liver, kidneys and thyroid gland; neurodevelopmental deficits 67 
including inhibited foetal and infant development; and various cancers (Costa, 2008). 68 
Furthermore, in vitro studies have demonstrated that doses as low as 5µM can induce oxidative 69 
stress and disrupt steroidogenesis, with high level PBDE exposure resulting in pregnancy 70 
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failure (Lefevre et al., 2016).  Exposure to the Penta-BDE formulation can activate the aryl 71 
hydrocarbon (Ah) –receptor (Gu et al., 2012), cause a reduction in hepatic vitamin A levels, 72 
impair neurodevelopment, and induce carcinogenesis (D'Silva et al., 2004, Hornung et al., 73 
1996). Similarly, the OctaBDE formulation causes developmental toxicity, whilst the DecaBDE 74 
formulation is believed to be the least toxic as it contains higher molecular weight congeners 75 
that have relatively decreased cell membrane permeability, and are more readily metabolised 76 
(D'Silva et al., 2004, Chevrier et al., 2013). However, it is also believed that higher brominated 77 
congeners (such as BDE-209, which makes up >95% of the Deca-BDE formulation (La 78 
Guardia et al., 2006)) can be broken down by physical and biological processes to form lower 79 
brominated PBDE congeners that are found readily in Penta- and Octa-BDE formulations 80 
(D'Silva et al., 2004). Data on human health effects of HBCDD exposure is limited - Eggesbø 81 
et al., 2011 reported that it does not appear to have an effect on the human thyroid (Eggesbø et 82 
al., 2011). However,  Dorosh et al. (2011) suggested its potential endocrine disrupting ability 83 
by altering oestrogenic activity.. Further, Genskow et al. (2015) has suggested that HBCDD 84 
exposure damages dopaminergic neurons, with consequences for neurological and endocrine 85 
system function, and there is evidence for reduced birthweight and significant adverse 86 
neurodevelopment, including impaired motor skills and increased anxiety levels in rodent 87 
models (Maurice et al., 2015). 88 
 89 
Concerns over the toxicity of these BFRs led to bans on Penta- and Octa-BDE technical 90 
products within Europe in 2003, and globally in 2009 under the UNEP Stockholm Convention 91 
(SC) (Stockholm Convention, 2009). Significant restrictions were placed on the DecaBDE 92 
technical product in 2008 (Deffree, 2008), and it was included in the SC in 2017 (Chemical 93 
Watch, 2017), alongside HBCDD in 2013 (Health and Environment Alliance, 2013). Whilst 94 
these bans will eventually lead to reduced exposure, they only prevent the new manufacture 95 
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and new use of these chemicals, meaning that BFRs will still be incorporated into products 96 
already on the market, and currently in circulation. Both PBDEs and HBCDDs are still 97 
regularly found in various indoor microenvironments across the world (Sahlstrom et al., 2015, 98 
Johnson et al., 2013, Ni and Zeng, 2013, Harrad and Abdallah, 2015), meaning that humans 99 
will continue to be exposed to them for the foreseeable future. Given that exposure to these 100 
chemicals can lead to a plethora of toxic health effects, it is vital that they are continually 101 
monitored in general populations across the globe.  102 
 103 
The aims of this study are to provide the first data on HBCDD exposure in the UK population 104 
using human sera, and to provide updated assessment of human exposure to PBDEs and 105 
HBCDDs in reproductive-aged women in the UK. The relationship between these BFRs and 106 
various demographics (weight, body mass index (BMI), and age) will also be assessed to gain 107 
insight into any potential health effects caused by target compounds. We include a temporal 108 
assessment of HBCDD and PBDE body burdens in the UK, and a comparison of UK body 109 
burdens with available data from other cross-sectional populations, globally.  110 
 111 
2.0 Materials & Methods 112 
2.1 Sample Collection and Preparation 113 
This prospective cohort study was performed within the Hull IVF Unit, UK in 2014, following 114 
approval by The Yorkshire and The Humber NRES ethical committee, UK (approval number 115 
02/03/043). A total of 59 women were recruited into the study, whose baseline characteristics 116 
are shown in Table 1. Inclusion criteria were age 20-45 years, BMI ≤35 and undergoing in vitro 117 
fertilisation. Patients with known immunological disease, diabetes, renal or liver insufficiency, 118 
acute or chronic infections, or inflammatory diseases were excluded from the study.  119 
 120 
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A fasting blood sample was collected on day 21 of the luteal phase of the cycle, and prior to 121 
commencing IVF treatment. Samples were centrifuged, aliquoted, and stored at -80 °C. 122 
Samples were shipped on dry ice to The Queensland Alliance for Environmental Health 123 
Sciences at The University of Queensland, Australia for further analysis. 124 
 125 
2.2 Lipid Analyses of Samples 126 
Serum (300µL) was analysed for cholesterol (TC) and triglycerides (TG) by Sullivan 127 
Nicolaides Pathology (SNP), Australia. Total lipid (TL) concentration (mg/dL) was calculated 128 
using the following equation (Phillips et al., 1989). 129 
𝑇𝑇𝑇𝑇 = 2.27.𝑇𝑇𝑇𝑇 + 𝑇𝑇𝐺𝐺 + 62.3 130 
 131 
2.3 Sample Extraction & Clean-up 132 
Five mL of serum was aliquoted into a 50 mL polypropylene centrifuge tube. Samples were 133 
spiked with 5 ng each of internal standards (13C12-labelled BDEs -28, -47, -99, -100, -153, -134 
154, -183, 13C12-labelled α-, β- and γ-HBCDD). Samples were vortexed for approximately 1 135 
minute and left to stand for 30 minutes. 6 mL acetonitrile, 3 mL milliQ, 5 g anhydrous MgSO4 136 
and 1 g NaCl were added along with a ceramic homogenizer. Samples were manually shaken 137 
for 1 minute prior to centrifuging at 4500 RPM for 8 minutes at 10 °C. The supernatant layer 138 
was collected and transferred to a glass tube. The extract was evaporated to near-dryness on a 139 
hot plate using a gentle stream of nitrogen and reconstituted in approximately 1 mL hexane. 1 140 
mL >98% concentrated sulfuric acid was added and the sample was vortexed for at least 30 141 
seconds. The aqueous and organic layers were left to separate overnight at <4 °C. The 142 
supernatant layer was transferred directly onto a silica solid phase extraction cartridge (Supelco 143 
LC-Si 3mL/500 mg), preconditioned with 6 mL dichloromethane, followed by 6 mL hexane. 144 
The sample was allowed to load onto the cartridge gravimetrically. Target compounds were 145 
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eluted into a glass tube using 6 mL hexane, followed by 8 mL dichloromethane at 146 
approximately 2 mL/min. The sample was evaporated to near-dryness and reconstituted in 100 147 
µL iso-octane containing 2.5 ng 13C12-PCB-141 and 13C12-TBBPA as recovery standards. After 148 
analysis for PBDEs by high resolution gas chromatography coupled with high resolution mass 149 
spectrometry (HRGC/HRMS) extracts were solvent exchanged into 100 µL methanol and 150 
analysed for HBCDD via liquid chromatography tandem mass spectrometry (LC-MS/MS). 151 
 152 
2.4 Instrumental Analysis 153 
For PBDE analysis by HRGC/HRMS,a Thermofisher TRACE 1300 gas chomatograph was 154 
coupled to a Thermofisher DFS mass spectrometer. The injector was operated in splitless mode 155 
with separation achieved on an Agilent DB-5ms column (30 m length x 0.25 mm in diameter 156 
x 0.25 µm film thickness). Experiments were conducted in MID mode at 10,000 resolution 157 
(10% valley definition). The inlet, transfer line and source were held at 250 ºC, 280 ºC and 280 158 
ºC respectively. The flow rate was maintained at 1.0 mL/min. Details of acquisition ions for 159 
PBDEs are outlined in the supporting information (SI, (Tables S1 and S2 respectively). 160 
 161 
HBCDDs (α-, β- and γ-) were measured in serum samples using an AB/Sciex API 5500Q mass 162 
spectrometer (AB/Sciex, Concord, Ontario, Canada) coupled to a Shimadzu Nexera HPLC 163 
system (Shimadzu Corp., Kyoto, Japan). The mass spectrometer (MS) was operated in multiple 164 
reaction monitoring mode using negative electrospray ionisation. A volume of 5 µL was 165 
injected. Separation was achieved using a Kinetex XB C18, 50 x 2.0 mm 1.7 µm column 166 
(Phenomenex, Torrance CA) using a mobile phase gradient of 85% methanol, ramping up to 167 
100% methanol over 6 min and then holding for 4 min at a flow rate of 0.3 mL/min. Full MS 168 
parameters have been provided previously (Drage et al., 2017). 169 
 170 
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2.5 Quality Control 171 
A blank sample was extracted as every 6th sample (n=10), alternating between 5 mL of MilliQ 172 
water (n=5) and 5 mL bovine calf serum (n=5). If a target compound was detected in a blank 173 
at less than 5% of measured sample concentration, then no correction occurred; if blank 174 
concentration was 5–25% of measured sample concentration, the blank concentration was 175 
subtracted from that of the sample.  176 
 177 
In the absence of a certified QC sample, method precision and accuracy were determined using 178 
bovine serum (5mL, n=5) fortified with target compounds. 30 µL of a solution containing 2 179 
ng/mL of all target compounds in methanol was added to each aliquot, which was then vortexed 180 
for 1 minute and left at <4 °C overnight. Good accuracy and precision was found for all target 181 
analytes with average recoveries between 80-120% and a relative standard deviation <15% 182 
(Table S2).  183 
 184 
Internal standard recoveries of 13C-labelled HBCDDs were estimated by expressing their ratio 185 
with 13C12-TBBPA in the samples as a percentage of the same ratio in a non-extracted side-186 
spike (NESS). The recoveries of the remaining internal standards was calculated using their 187 
ratio with 13C12-PCB-141. Average recoveries ranged from 59% (13C12-BDE-28) to 84 % 188 
(13C12-BDE-154). Details of recoveries of all internal standards are provided in the SI (Table 189 
S3).  190 
 191 
2.6 Statistical Analysis 192 
For the purposes of calculations of averages and all statistical testing where a compound was 193 
below the limit of quantification (LOQ), values were set to half the limit of detection (LOD). 194 
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All statistical tests were computed using Microsoft Excel 2010 and SPSS for Windows version 195 
22.0. 196 
 197 
3.0 Results & Discussion 198 
This study reports the first data for HBCDD in human serum from the UK. Sum of α-, β-, and 199 
γ-HBCDD (ΣHBCDD) was detected in 40 out of 59 samples at a concentration range of <0.3 200 
– 13 ng/g lipid. The average concentration measured was 2.2 ng/g lipid, the geometric mean 201 
was 0.75 ng/g lipid and the median was 1.8 ng/g lipid (Table 2).  202 
 203 
The dominant stereoisomer was α-HBCDD with an average contribution of 82% (0-100%) 204 
towards ΣHBCDD, was followed by γ-HBCDD (average contribution = 17%). β-HBCDD was 205 
only detected in one sample where it contributed 25% to a ΣHBCDD concentration of 11 ng/g 206 
lipid. This stereoisomer pattern in human sera is consistent with previous studies from Australia 207 
(Drage et al., 2017), India (Devanathan et al., 2012), Sweden (Weiss et al., 2006), Canada 208 
(Ryan et al., 2006) and Japan (Kakimoto et al., 2008). The dominance of α-HBCDD in human 209 
and other biotic samples is likely due to more effective transformation of β- and γ- HBCDD to 210 
α-HBCDD through increased metabolic rate, combined with preferential accumulation of the 211 
α-stereoisomer (Fonnum and Mariussen, 2009). 212 
 213 
PBDEs were detected in measurable concentrations in 56 out of 59 samples with a ΣPBDE 214 
(sum of BDEs -28, 47, -99, -100, -153, -154 and -183) concentration range of <0.4 – 15 ng/g 215 
lipid. The average concentration was 2.4 ng/g lipid, the geometric mean was 1.4 ng/g lipid and 216 
the median was 1.9 ng/g lipid (Table 3). BDEs -153 and -47 were the dominant congeners, 217 
contributing an average of 40% and 37% respectively, to the average ΣPBDE congener profile. 218 
The remaining PBDE content came from BDEs -100, -99 and -28 with average contributions 219 
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of 12%, 8.5% and 2.6% respectively. BDEs -154 and -183 were not detected in any of the 220 
samples. The dominance of BDEs -47 and -153 in human serum is consistent with much of the 221 
previous literature including previous measurements of serum from the UK, USA (Sjödin et 222 
al., 2004, Sjödin et al., 2008), Japan (Akutsu et al., 2008), Greece (Kalantzi et al., 2011), 223 
Romania (Dirtu et al., 2006) and France (Brasseur et al., 2014). 224 
3.1 Demographic trends: Age, Weight and BMI 225 
Despite the narrow age range of participants (23-42 years), Figure 1 suggests that there is a 226 
decrease in HBCDD levels with age (R2 = 0.105). However, a linear regression analysis shows 227 
this to be insignificant (p = 0.08). There were no observed associations between PBDE levels 228 
of participants and their age. This may be due to the limited sample size and age range of 229 
participants in the study. Previous studies have demonstrated higher levels of PBDEs in 230 
children and infants (Toms et al. 2009), however this study only investigated mothers of child-231 
bearing age. 232 
A linear regression suggested a weak positive association between HBCDD levels and 233 
bodyweight of the participant (R2 = 0.075, p = 0.036; Figure S1a). However, when corrected 234 
for height by using BMI instead of weight (Figure S1b), this association was no longer 235 
significant (R2 = 0.057, p = 0.068). There were no observed associations between bodyweight 236 
or BMI and PBDE levels in participants from this study. 237 
3.2 Temporal Trends: Exposure in the United Kingdom 238 
Data on human exposure to HBCDDs in the UK is scarce, with only two previous studies 239 
measuring breast milk concentrations from samples collected between 2008 and 2011 (Harrad 240 
and Abdallah, 2015, Abdallah and Harrad, 2011), and prior to legislative ban. Median 241 
ΣHBCDD concentrations from this study (1.8 ng/g lipid, 2014) were significantly  lower 242 
(ANOVA, p<0.0001) than samples from 2008-2010 and 2010-2011 (3.8  and 5.2 ng/g lipid, 243 
respectively) (Abdallah and Harrad, 2011, Harrad and Abdallah, 2015). A recent study of 244 
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breastmilk from 10 women in UK collected in 2014-2015 by Tao et al. (2017) reported similar 245 
HBCDD levels as the serum measures in our study (median: 2.9 ng/g lipid, range: 0.7-7.1 ng/g 246 
lipid) (Figure 2). This is suggestive of a temporal trend to decreasing HBCDD exposure in UK 247 
women. While there is some precedent for comparing serum and breast milk biomarker 248 
concentrations as indicative of overall body burden, the samples were collected over a 249 
relatively short period of time (2008 to 2015, across the 4 different studies), for a 250 
comprehensive temporal assessment of exposure. Furthermore, HBCDDs were only subject to 251 
legislative bans in 2013 – one year before samples were collected for this study (Health and 252 
Environment Alliance, 2013), meaning that it is too early to assess the impact of legislative 253 
action on HBCDD exposures in the UK population.  254 
 255 
The range of ΣPBDE concentrations in this study are similar to those found in Newcastle-256 
Upon-Tyne, UK in the same year (1.0-16 ng/g lipid (Bramwell et al., 2014)) and from 257 
Birmingham in 2010, 2010-11 and 2014-15 (Abdallah and Harrad, 2014, Harrad and Abdallah, 258 
2015, Tao et al., 2017). Median ∑PBDE concentrations are approximately 3 times lower than 259 
those found in serum (5.6 ng/g lipid (Thomas et al., 2006)) and breast milk (6.3 ng/g lipid 260 
(Kalantzi et al., 2004))  collected from Lancaster and London from 2001 to 2003 (Figure 3). 261 
This would suggest PBDE levels have fallen since the 2004 bans of Penta- and Octa- BDE in 262 
the EU (Birnbaum and Staskal, 2004). However, breastmilk samples collected in 2014-15 by 263 
Tao et al. (2017) contradict this finding with median concentrations of 5.8 ng/g lipid. This is 264 
likely due to small sample size (n=10), and high variability both between-individuals, and 265 
between geographical regions of the UK.  However, it is pertinent to note that in our study, 266 
there was a 95% detection rate of PBDEs in UK human serum 8 years after these bans, and 267 
Tao et al. (2017) had a 100% detection rate in human milk more than a decade later. This 268 
demonstrates that UK populations are still continuously exposed to PBDEs despite legislative 269 
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bans, and further action may be required to reduce body burden at the population level. Similar 270 
temporal declines over a period of 10 years have also been suggested for HBCDDs in Australia 271 
(Drage et al., 2017), (Toms et al., 2012), and Canada (Ryan and Rawn, 2014), however both 272 
compounds are still regularly detected in humans highlighting the need for constant monitoing 273 
of their concentrations in humans and the environment. 274 
 275 
3.3 Comparison with global biomonitoring data 276 
Literature of serum measures of HBCDD is scarce, however there are a number of studies 277 
reporting HBCDDs in milk from various countries (Table 1). The average concentration of 278 
HBCDDs from this study (2.2 ng/g lipid) is at the lower end of the range of concentrations 279 
found across the world (not detected – 43 ng/g lipid) and half the average concentration 280 
worldwide (4.6 ng/g lipid). Concentrations were similar to breast milk collected in Canada in 281 
1992-2005 (Ryan and Rawn, 2014) and serum from Belgium in 2007 (Roosens et al. 2009), 282 
whilst they were 3-10 times higher than milk collected from the Philippines in 2008 283 
(Malarvannan et al. 2013b), and India in 2009 (Devanathan et al. 2012). Furthermore, 284 
Sahlström et al. (2014) did not detect HBCDD in any serum collected from 48 individuals in 285 
Sweden between 2009 and 2010. Average HBCDD concentrations in serum collected in South 286 
Korea from 2009-2010 (Kim and Oh, 2014) was approximately 4 times higher than serum from 287 
this study, whilst milk collected in Spain from 2006-2007 was almost 20 times higher (Eljarrat 288 
et al 2009).  289 
 290 
Human biomonitoring studies for PBDEs are more prevalent in the literature than for 291 
HBCDDs. The mean ∑PBDE (2.4 ng/g lipid) concentration from this study was at the lower 292 
end of the range of ∑PBDE levels measured between 2009 and 2015 internationally (Table 2), 293 
but similar to (lipid normalised) ∑PBDE concentrations of breastmilk and serum from other 294 
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regions of the UK ((Bramwell et al., 2014, Tao et al., 2017, Harrad and Abdallah, 2015), 295 
Norway (Cequier et al., 2015), Denmark  (Vorkamp et al., 2014), and some regions of China 296 
(Wu et al., 2017, Wang et al., 2016). Serum levels of ∑PBDEs in this study were approximately 297 
2.5 times higher than breastmilk from Sweden (Darnerud et al., 2015), but between 3 and 20 298 
times lower than serum collected across USA (Watkins et al., 2011, Butt et al., 2016, Makey 299 
et al., 2014, Zota et al., 2013, Hurley et al., 2017). Furthermore, serum from 6 individuals in 300 
Laizhou Bay, China, with no known occupational exposure were  up to 300 times higher than 301 
from this study (Wang et al., 2014). 302 
 303 
Major strengths of this study include relatively large sample size (59) as well as the the pairing 304 
of BFR body burdens with demographic data such as age, weight and height. A potential 305 
weakness of the  study is the fact that all participants were undergoing in vitro fertilisation. 306 
However, this was overcome by the fact that they were an otherwise normal population, and 307 
patients with any known conditions were excluded from the study, making it an otherwise 308 
normal population. 309 
 310 
4.0 Conclusions 311 
Here we present data confirming that reproductive aged women from the UK continue to be 312 
exposed to both HBCDDs and PBDEs. Data from this study suggests that HBCDD levels 313 
decrease with age, however further sampling of a wider age range would be required to further 314 
investigate this. It also suggests a positive association between bodyweight and HBCDD levels, 315 
which likewise requires a large-scale study to confirm this. The data suggests that 10 years 316 
after their European ban, PBDE body burden has begun to decrease in the UK. Whilst it is too 317 
early draw any firm conclusions for HBCDDs, they appear to be following a similar pattern to 318 
PBDEs, with levels decreasing by a factor of >2.5 since 2010, a trend that has also been 319 
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observed in Australia. Whilst human body burdens appear to be decreasing, both PBDEs and 320 
HBCDD are still consistently detected in human serum, despite legislative action limiting their 321 
production and use, and highlighting the need to continuously assess human exposure and the 322 
effectiveness of policy aimed at reducing exposure.   323 
 324 
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Figures and Tables 622 
Table 1: Summary population characteristics 623 
  
Number of participants 59 
Age (years) 32 
23-42 
Height (cm) 165 
148-191 
























  624 
This accepted manuscript is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The published version is at 
https://www.sciencedirect.com/science/article/pii/S0013935119304281?via%3Dihub 
Table 2 ∑HBCDD concentrations (ng/g lipid) in humans from this study and other studies internationally from 2002-2015 
Country Matrix n Mean Range Ref 
Europe      
UK Serum 59 individuals 2.2 <0.3 -  12.6 This Study 
UK Milk 10 individuals 3.2 0.7 - 7.1 Tao et al. (2017) 
UK Milk 25 individuals 5.95 1 - 22 Abdallah and Harrad (2011) 
UK Milk 10 individuals 6.5 0.3 - 21 Harrad and Abdallah (2015) 
Belgium Serum 16 individuals 2.9 <0.5 - 11 Roosens et al. (2009) 
Belgium Milk 1 pooled sample 1.5 n/a Colles et al. (2008)  
Czech 
Republic Adipose 98 individuals 1.2 <0.5-7.5 Pulkrabova et al. (2009) 
France Milk 26 n/a <1-5 Antignac et al. (2006) 
France Adipose 26 n/a 1-3 Antignac et al. (2006) 
Greece Serum 61 individuals 3.39 0.49-39 Kalantzi et al. (2011) 
Ireland Milk 11 pools 3.5 1.7-5.9 Pratt et al. (2013) 
Netherlands Cord Serum 12 0.2 0.2-4.3 Meijer et al. (2008) 
Netherlands Serum 91 0.2 0.1-0.36 Peters (2004) 
Norway Milk 10 individuals n/a nd-0.13 Polder et al. (2008a,b) 
Norway Milk 393 individuals 1.7 <0.2-31 Thomsen et al. (2009a) 
Norway Milk 12 individuals n/a 0.25-2 Thomsen et al. (2003) 
Norway Milk 85 individuals n/a 0.4-20 Thomsen et al. (2005) 
Norway Milk 67 Individuals n/a nd-3 Thomsen etal. (2009b) 
Norway Milk 193 individuals 1.1 0.1-31 Eggesbø et al. (2011) 
Russia Milk 23 individuals 0.71 nd-1.67 Polder et al. (2008a) 
Russia Milk 14 individuals 0.47 nd-1.15 Polder et al. (2008a) 
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Spain Milk 33 individuals 43 <LOQ-190 Eljarrat et al. (2009) 
Sweden Milk 14 pools n/a 0.1-0.6 Fangstrom et al. (2008) 
Sweden Milk 204 individuals n/a 0.09-10 Glynn et al. (2011) 
Sweden Serum 50 individuals 0.46 <0.24-3.4 Weiss et al. (2006) 
Sweden Serum 48 individuals 0 not detected Sahlström et al. (2014) 
Asia           
India Milk 55 individuals 0.53 <0.05 - 13 Devanathan et al. (2012) 
China Milk 103 individuals 4.29 <LOQ-78 Shi et al. (2013a) 
China Serum 42 pools 0.86 <LOQ - 7.2 Shi et al. (2013b) 
China Milk 12 individuals 2.2 <LOQ - 5.5 Shi et al. (2013b) 
Philippines Milk 33 individuals 0.86 0.13 - 3.2 Malarvannan et al. (2009) 
Philippines Milk 30 individuals 0.21 <0.01-0.91 Malarvannan et al. (2013b) 
South Korea Serum 76 individuals 8.6 <dl-166 Kim and Oh (2014) 
Vietnam Milk 9 individuals n/a 0.07 - 1.4 Tue et al. (2010) 
Vietnam Milk 4 individuals n/a 0.11 - 0.97 Tue et al. (2010) 
Africa           
South Africa Milk 28 individuals 0.55 <0.23 - 1.4 Darnerud et al. (2011) 
North America         
Canada Milk 8 3.8 0.4-19 Ryan et al. (2006) 
Canada Serum 59 pools 1 0.33 - 8.9 Rawn et al. (2014) 
Canada Milk 34 individuals 1.8 0.1-28 Ryan and Rawn (2014) 
USA Milk 9 0.5 0.2-0.9 Ryan et al. (2006) 
Oceania           
Australia Serum 63 pools 3.1 <0.5-36 Drage et al. 2017 
Australia Milk 12 pools 6.6 <LOQ - 19 Toms et al. (2012a) 
Australia Serum 40 pools 0.45 <0.1-1.9 Drage et al. 2019 
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Table 3 ∑PBDE concentrations (ng/g lipid) in humans from this study and other studies 
internationally from 2009-2015 
 
Country Year Matrix n Mean Median Range Ref 
Europe        
UK 2014 Serum 59 individuals 2.4 1.9 <0.2 - 15 This Study 
UK 2012 Serum 20 individuals N/A 2.4 42370 Bramwell et al. 20  
UK 2012 Milk 8 individuals N/A 4.8 46753 Bramwell et al. 20  
UK 2010 Milk 25 individuals 5.9 5 0.2 - 26 Abdallah & Harra  2014 
UK 2010-11 Milk 10 individuals 5.1 3.7 1.3 - 13 Harrad & Abdalla  2015 
UK 2014-2015 Milk 10 individuals 6.5 5.8 1.7 - 14 Tao et al. 2017 
Denmark 2011 Serum 100 individuals 7.7 7.7 
<LOQ - 
18 Vorkamp et al. 20  
Norway 2012 Serum 46 individuals 3.6 2.3 0.1 - 23 Cequier et al. 201  
Sweden 2010 Milk 3 pools 0.73 0.77 0.58 - 0.84 Darnerud et al. 20  
Asia        
China 2011 Serum 12 pools 190 N/A 80-780 Wang et al. 2014 
China 2012 Serum 6 individuals N/A 13 4.3 - 42 Chen et al. (2014  
China 2013 Serum 10 pools 25 26 13 - 41 Li et al. 2017 
China 2014 Serum 32 individuals 7.8 5.6 1.1 - 39 Wang et al. 2016 
China 2014 Serum 9 individuals 5.6 N/A 0.42 - 27 Wu et al. 2017 
North America        
USA 2009 Serum 31 individuals 28 N/A 3.5 - 350 Watkins et al. 201  
USA 2008-2010 Serum 43 individuals 28 N/A 
0.71 - 
250 Butt et al. 2016 
USA 2010-2011 Serum 52 individuals 6.2 N/A 0.25 - 97 Makey et al. 201  
USA 2011-2012 Serum 36 individuals 52 N/A N/A Zota et al. 2013 
USA 2011-2015 Serum 
1253 
individuals 23 N/A N/A Hurley et al. 201  
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Figure 2 Temporal variation of mean HBCDD concentrations of serum and breast milk 
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Figure 3 Temporal variation of mean PBDE concentrations of serum from UK adults 
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